ABSTRACT
We present the case of a 51 years-old patient, with the diagnosis of a giant borderline Phyllodes tumor. We present her clinical record, treatment and the follow-up care in the next two years and a half. We remark the importance of being conscious about health care
Presentamos el caso de un paciente de 51 años con diagnóstico de tumor gigante de Phyllodes en el límite. Presentamos su historia clínica, tratamiento y seguimiento en los próximos dos años y medio. Destacamos la importancia de ser conscientes de la atención a la salud
Subject(s)
Humans , Female , Middle Aged , Phyllodes Tumor/pathology , Continuity of Patient Care/statistics & numerical data , Breast Neoplasms/pathology , Neoplasms, Fibroepithelial/pathology , Mammaplasty/methods , Breast Neoplasms/therapy , Phyllodes Tumor/therapyABSTRACT
BACKGROUND: The main purpose of the present study is to evaluate whether treatment with long-acting human glucagon-like peptide-1 liraglutide was associated with an improvement of excessive daytime sleepiness (EDS) in obese subjects with type-2 diabetes. METHODS: This single-centre retrospective study included 158 obese (body mass index [BMI] ≥ 30 kg/m(2)) adult subjects with type-2 diabetes who were initiated with liraglutide treatment at least 3 months before study inclusion. Data of the Epworth Sleepiness Scale (ESS), anthropometric parameters, glucose-control and metabolic parameters were collected at liraglutide initiation (baseline) and at months 1 and 3 after liraglutide initiation. RESULTS: Significant reductions in ESS score were achieved at months 1 (-1.3 ± 2.8, p < 0.001) and 3 (-1.5 ± 3.0, p < 0.001) after liraglutide introduction. After 3 months of treatment with liraglutide, significant changes in body weight (p < 0.001), BMI (p < 0.001), waist (p < 0.001) and neck circumferences (p < 0.005), HbA1c (p < 0.001), mean blood glucose (p < 0.001), fasting plasma glucose (p < 0.001), triglycerides (p < 0.01) and total cholesterol (p < 0.001) were achieved. CONCLUSIONS: After 3 months of treatment with liraglutide a significant reduction in EDS was observed in obese subjects with type-2 diabetes. Besides this, significant changes in body weight and metabolic parameters of diabetes control were also accomplished. Further investigation is required to determine whether liraglutide could improve other abnormal sleep patterns and obstructive sleep apnoea.
